PTI-2

PTI-2
Legal status
Legal status	CA: Schedule II; DE: NpSG (Industrial and scientific use only); UK: Class B;
Identifiers
	IUPAC name N-(2-methoxyethyl)-N-((2-(1-pentyl-1H-indol-3-yl)thiazol-4-yl)methyl)propan-2-amine;
CAS Number	1400742-45-1;
ChemSpider	58827849;
UNII	W0MO88040Q;
Chemical and physical data
Formula	C23H33N3OS
Molar mass	399.60 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCCCCN1C=C(C2=CC=CC=C21)C3=NC(CN(C(C)C)CCOC)=CS3;
	InChI InChI=1S/C23H33N3OS/c1-5-6-9-12-26-16-21(20-10-7-8-11-22(20)26)23-24-19(17-28-23)15-25(18(2)3)13-14-27-4/h7-8,10-11,16-18H,5-6,9,12-15H2,1-4H3; Key:PSAKYYVEVVAWJL-UHFFFAOYSA-N;

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

PTI-2 (SGT-49) is an indole-based synthetic cannabinoid.^[1] It is one of few synthetic cannabinoids containing a thiazole group and is closely related to PTI-1. These compounds may be viewed as simplified analogues of indole-3-heterocycle compounds originally developed by Organon and subsequently further researched by Merck.^[2]^[3]^[4]

References

^ "PTI-2". Cayman Chemical. Retrieved 8 July 2015.
^ US 7700634, Adam-Worrall J, Morrison AJ, Wishart G, Kiyoi T, McArthur DR, "(Indol-3-yl) heterocycle derivatives as agonists of the cannabinoid CB1 receptor.", issued 20 April 2010, assigned to Organon NV
^ US 7763732, Paul David Ratcliffe PD, Adam-Worrall J, Morrison AJ, Francis SJ, Kiyoi T, "Indole Derivatives", issued 27 July 2010, assigned to Organon NV
^ Kiyoi T, Adam JM, Clark JK, Davies K, Easson AM, Edwards D, et al. (March 2011). "Discovery of potent and orally bioavailable heterocycle-based cannabinoid CB1 receptor agonists". Bioorganic & Medicinal Chemistry Letters. 21 (6): 1748–53. doi:10.1016/j.bmcl.2011.01.082. PMID 21316962.

This cannabinoid related article is a stub. You can help Wikipedia by expanding it.

[1] "PTI-2". Cayman Chemical. Retrieved 8 July 2015.

[2] US 7700634, Adam-Worrall J, Morrison AJ, Wishart G, Kiyoi T, McArthur DR, "(Indol-3-yl) heterocycle derivatives as agonists of the cannabinoid CB1 receptor.", issued 20 April 2010, assigned to Organon NV

[3] US 7763732, Paul David Ratcliffe PD, Adam-Worrall J, Morrison AJ, Francis SJ, Kiyoi T, "Indole Derivatives", issued 27 July 2010, assigned to Organon NV

[pmid21316962-4] Kiyoi T, Adam JM, Clark JK, Davies K, Easson AM, Edwards D, et al. (March 2011). "Discovery of potent and orally bioavailable heterocycle-based cannabinoid CB1 receptor agonists". Bioorganic & Medicinal Chemistry Letters. 21 (6): 1748–53. doi:10.1016/j.bmcl.2011.01.082. PMID 21316962.

[1]

[2]

[3]

[4]

See also

References